<SEC-DOCUMENT>0001213900-25-032062.txt : 20250415
<SEC-HEADER>0001213900-25-032062.hdr.sgml : 20250415
<ACCEPTANCE-DATETIME>20250415160043
ACCESSION NUMBER:		0001213900-25-032062
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250415
FILED AS OF DATE:		20250415
DATE AS OF CHANGE:		20250415

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PURPLE BIOTECH LTD.
		CENTRAL INDEX KEY:			0001614744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37643
		FILM NUMBER:		25839414

	BUSINESS ADDRESS:	
		STREET 1:		4 OPPENHEIMER STREET
		STREET 2:		SCIENCE PARK
		CITY:			REHOVOT
		STATE:			L3
		ZIP:			7670104
		BUSINESS PHONE:		97239333121

	MAIL ADDRESS:	
		STREET 1:		4 OPPENHEIMER STREET
		STREET 2:		SCIENCE PARK
		CITY:			REHOVOT
		STATE:			L3
		ZIP:			7670104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Kitov Pharma Ltd.
		DATE OF NAME CHANGE:	20180125

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Kitov Pharmaceuticals Holdings Ltd.
		DATE OF NAME CHANGE:	20140724
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0238395-6k_purplebio.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C.&nbsp;20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of&nbsp;the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of April 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: 001-37643</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURPLE BIOTECH LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>4 Oppenheimer Street, Science Park, Rehovot
7670104, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Purple Biotech Ltd. (the
&ldquo;Company&rdquo; or the &ldquo;Registrant&rdquo;) announced that the Company&rsquo;s Annual Meeting of Shareholders (the &ldquo;Annual
Meeting&rdquo;) held on Tuesday, April 15, 2025, at 4:30 p.m. Israel time was convened and adjourned, without any business being conducted,
due to lack of the required quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Annual Meeting therefore
was adjourned to Tuesday, April 22, 2025, at 4:30 p.m. Israel time, at the offices of the Company at 4 Oppenheimer Street, Science Park,
Rehovot, Israel, to allow additional time for the Company&rsquo;s shareholders to vote on the proposals set forth in the notice and proxy
statement for the Annual Meeting attached as Exhibit 99.1 to the Form 6-K filed by the Company with the U.S. Securities and Exchange Commission
on February 28, 2025. No changes have been made to the proposals to be voted on at the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Only shareholders and holders
of the Company&rsquo;s American Depositary Shares (&ldquo;ADSs&rdquo;) of record at the close of business in New York on March 6, 2025
(the &ldquo;Record Date&rdquo;), are entitled to vote at the Annual Meeting. You are also entitled to vote at the Annual Meeting if you
are a beneficial owner who holds ordinary shares or ADSs through a broker, bank or other nominee as of the Record Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the period of adjournment,
the Company will continue to solicit votes from its shareholders with respect to the proposals set forth in the proxy statement. Votes
previously submitted in respect of the Annual Meeting will be voted at the adjourned Annual Meeting unless properly revoked.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Incorporation by Reference</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">This Report on Form 6-K,
including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant&rsquo;s Registration Statement
on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1614744/000114420416103812/v440298_s8.htm">Form S-8</A>&nbsp;filed with the Securities
and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant&rsquo;s Registration Statement on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1614744/000121390017006184/fs82017_kitovpharma.htm">Form
S-8</A>&nbsp;filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant&rsquo;s
Registration Statement on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1614744/000121390018009254/ff32018_kitovpharma.htm">Form
F-3</A>, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195),
the Registrant&rsquo;s Registration Statement on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1614744/000121390019005134/fs82019_kitovpharmaltd.htm">Form
S-8</A>&nbsp;filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant&rsquo;s
Registration Statement on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1614744/000121390019018149/ff32019_kitovpharma.htm">Form
F-3</A>&nbsp;filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant&rsquo;s
Registration Statement on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1614744/000121390019027099/ff12019_kitovpharma.htm">Form
F-1</A>&nbsp;filed with the Securities and Exchange Commission on December 27, 2019 (Registration file number 333-235729), the Registrant&rsquo;s
Registration Statement on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1614744/000121390020012007/ea121429-f3_kitovpharma.htm">Form
F-3</A>&nbsp;filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333-238229), the Registrant&rsquo;s
Registration Statement on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1614744/000121390020012852/ea122048-s8_kitovpharma.htm">Form
S-8</A>&nbsp;filed with the Securities and Exchange Commission on May 18, 2020 (Registration file number 333-238481), each of the Registrant&rsquo;s
Registration Statements on&nbsp;Form
F-3&nbsp;filed with the Securities and Exchange Commission on July 10, 2020 (Registration file numbers <A HREF="http://www.sec.gov/Archives/edgar/data/1614744/000121390020017224/ea123998-f3_kitovpharma.htm">333-239807</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1614744/000121390020017228/ea124005-posam_kitovpharma.htm">333-233793</A>),
the Registrant&rsquo;s Registration Statement on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1614744/000121390022017815/ea157934-s8_purplebiotech.htm">Form
S-8</A>&nbsp;filed with the Securities and Exchange Commission on April 4, 2022 (Registration file number 333-264107) and the Registrant&rsquo;s
Registration Statement on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1614744/000121390023022248/ea175634-f3_purplebiotech.htm">Form
F-3</A>&nbsp;filed with the Securities and Exchange Commission on March 23, 2023 (Registration file number 333-270769), the Registrant&rsquo;s
Registration Statement on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1614744/000121390022078317/ea169732-f3_purplebiotech.htm">Form
F-3</A>, as amended, originally filed with the Securities and Exchange Commission on December 8, 2022 (Registration file number 333-268710),
the Registrant&rsquo;s Registration Statement on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1614744/000121390023081556/ea187369-f1_purplebio.htm">Form
F-1</A><U>,</U>&nbsp;as amended, originally filed with the Securities and Exchange Commission on October 30, 2023 (Registration file
number 333-275216) and the Registrant&rsquo;s Registration Statement on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1614744/000101376224000516/ea0209789-f1_purplebio.htm">Form
F-1</A><U>,</U>&nbsp;filed with the Securities and Exchange Commission on July 22, 2024 (Registration file number 333-280947), to be
a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed
or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 15, 2025</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURPLE BIOTECH LTD.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Gil Efron</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gil Efron</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
